Skip to Content
You are currently on the new version of our website. Access the old version .

226 Results Found

  • Brief Report
  • Open Access
33 Citations
4,501 Views
8 Pages

Susceptibility Testing Is Key for the Success of Cefiderocol Treatment: A Retrospective Cohort Study

  • Alexandre Bleibtreu,
  • Laurent Dortet,
  • Remy A. Bonnin,
  • Benjamin Wyplosz and ,
  • Sophie-Caroline Sacleux,
  • Liliana Mihaila,
  • Hervé Dupont,
  • Helga Junot,
  • Vincent Bunel and
  • on behalf of the Cefiderocol French Study Group
  • + 10 authors+ 5 authors

Cefiderocol is a novel siderophore cephalosporin, which has proven in vitro activity against carbapenem-resistant (CR) Gram-negative pathogens and stability towards all carbapenemases. The aim of this study was to describe the first cases of prescrip...

(This article belongs to the Section Antimicrobial Agents and Resistance)
  • Article
  • Open Access
35 Citations
7,539 Views
9 Pages

Disc Diffusion and ComASP® Cefiderocol Microdilution Panel to Overcome the Challenge of Cefiderocol Susceptibility Testing in Clinical Laboratory Routine

  • Gabriele Bianco,
  • Matteo Boattini,
  • Sara Comini,
  • Giuliana Banche and ,
  • Rossana Cavallo and
  • Cristina Costa
  • + 1 author+ 0 author

Cefiderocol susceptibility testing represents a major challenge for clinical microbiology. Although disc diffusion showed robustness to test cefiderocol susceptibility, large areas of technical uncertainty (ATU) are reported by current EUCAST breakpo...

(This article belongs to the Special Issue Bacterial Detection, Identification, and Antimicrobial Susceptibility Testing)
  • Brief Report
  • Open Access
5 Citations
1,796 Views
8 Pages

Efficacy of Cefiderocol Against Endophthalmitis Isolates

  • Brennan Schilling,
  • Michael Hii,
  • Hazel Q. Shanks,
  • Eric G. Romanowski and ,
  • Jonathan B. Mandell,
  • Robert M. Q. Shanks and
  • Michael Zegans
  • + 2 authors+ 0 author

23 December 2024

Background/Objectives: Endophthalmitis is an intraocular microbial infection that can lead to permanent blindness, even with prompt anti-microbial therapy. Multi-drug-resistant organisms are on the rise, potentially limiting the efficacy of current e...

(This article belongs to the Collection Antibiotics in Ophthalmology Practice)
  • Article
  • Open Access
30 Citations
4,832 Views
16 Pages

In Vitro Activity of Cefiderocol on Multiresistant Bacterial Strains and Genomic Analysis of Two Cefiderocol Resistant Strains

  • Michela Padovani,
  • Anna Bertelli,
  • Silvia Corbellini,
  • Giorgio Piccinelli and ,
  • Francesca Gurrieri and
  • Maria Antonia De Francesco
  • + 1 author+ 0 author

Cefiderocol is a new siderophore cephalosporin that is effective against multidrug-resistant Gram-negative bacteria, including carbapenem-resistant strains. The aim of this study was to evaluate the activity of this new antimicrobial agent against a...

(This article belongs to the Special Issue Epidemiology of ESBL-Producing Enterobacteriaceae)
  • Communication
  • Open Access
9 Citations
3,965 Views
9 Pages

Cefiderocol is a novel cephalosporin recently approved by the FDA to aid clinicians in the fight against multidrug-resistant (including carbapenem-resistant) gram-negative organisms. The primary objective of this study is to evaluate the 14- and 28-d...

(This article belongs to the Section Antibiotic Therapy in Infectious Diseases)
  • Article
  • Open Access
16 Citations
3,670 Views
15 Pages

Challenges Facing Two Outbreaks of Carbapenem-Resistant Acinetobacter baumannii: From Cefiderocol Susceptibility Testing to the Emergence of Cefiderocol-Resistant Mutants

  • Montserrat Rodríguez-Aguirregabiria,
  • Fernando Lázaro-Perona,
  • Juana Begoña Cacho-Calvo,
  • Mª Soledad Arellano-Serrano and ,
  • Juan Carlos Ramos-Ramos,
  • Eduardo Rubio-Mora,
  • Mariana Díaz-Almirón and
  • Mª José Asensio-Martín
  • + 3 authors+ 0 author

Carbapenem-resistant Acinetobacter baumannii (CRAB) infections are associated with poor outcomes depending on patient’s conditions, clinical severity and type of infection, and treatment is challenging given the limited therapeutic options avai...

(This article belongs to the Special Issue Antimicrobial Resistance and Therapy in Intensive Care Unit)
  • Communication
  • Open Access
15 Citations
3,237 Views
9 Pages

Synergistic Activity of Cefiderocol in Combination with Avibactam, Sulbactam or Tazobactam against Carbapenem-Resistant Gram-Negative Bacteria

  • Russell E. Lewis,
  • Marta Palombo,
  • Erica Diani,
  • Benedetta Secci and ,
  • Davide Gibellini and
  • Paolo Gaibani
  • + 1 author+ 0 author

6 August 2024

We investigated the activity of cefiderocol/β-lactamase inhibitor combinations against clinical strains with different susceptibility profiles to cefiderocol to explore the potentiality of antibiotic combinations as a strategy to contain the maj...

(This article belongs to the Section Cellular Pathology)
  • Article
  • Open Access
10 Citations
4,372 Views
11 Pages

Total and Unbound Pharmacokinetics of Cefiderocol in Critically Ill Patients

  • Noël Zahr,
  • Saik Urien,
  • Benoit Llopis,
  • Gaëlle Noé and ,
  • Nadine Tissot,
  • Kevin Bihan,
  • Helga Junot,
  • Clémence Marin,
  • Bochra Mansour and
  • Christian Funck-Brentano
  • + 7 authors+ 2 authors

Background: Cefiderocol is a siderophore cephalosporin antibiotic active against Gram-negative bacteria, including extended-spectrum beta-lactamase and carbapenemase-producing strains. The pharmacokinetics of cefiderocol has been studied in healthy s...

(This article belongs to the Special Issue Therapeutic Drug Monitoring and Pharmacokinetics-Based Individualization of Drug Therapy)
  • Article
  • Open Access
2 Citations
2,908 Views
11 Pages

Cefiderocol-Based Regimen for Acinetobacter NDM-1 Outbreak

  • Giovanna Travi,
  • Francesco Peracchi,
  • Marco Merli,
  • Noemi Lo Re and ,
  • Elisa Matarazzo,
  • Livia Tartaglione,
  • Alessandra Bielli,
  • Giorgia Casalicchio,
  • Fulvio Crippa and
  • Massimo Puoti
  • + 6 authors+ 1 author

Variable outcomes have been reported with cefiderocol in infections due to carbapenem-resistant Acinetobacter baumannii (CRAB). Nonetheless, it may be the only option for metallo-beta-lactamase-producing strains. We describe an outbreak of NDM-CRAB i...

(This article belongs to the Special Issue Infection Diagnostics and Antimicrobial Therapy for Critical Patient)
  • Review
  • Open Access
35 Citations
7,669 Views
22 Pages

Updates on the Activity, Efficacy and Emerging Mechanisms of Resistance to Cefiderocol

  • Gabriele Bianco,
  • Matteo Boattini,
  • Monica Cricca,
  • Lucia Diella and ,
  • Milo Gatti,
  • Luca Rossi,
  • Michele Bartoletti,
  • Vittorio Sambri,
  • Caterina Signoretto and
  • Paolo Gaibani
  • + 7 authors+ 2 authors

14 December 2024

In recent years, novel antimicrobials have been developed to counter the emergence of antimicrobial resistance and provide effective therapeutic options against multidrug-resistant (MDR) Gram-negative bacilli (GNB). Cefiderocol, a siderophore cephalo...

(This article belongs to the Special Issue Molecular Biology in Drug Design and Precision Therapy)
  • Review
  • Open Access
46 Citations
8,897 Views
19 Pages

Cefiderocol and Sulbactam-Durlobactam against Carbapenem-Resistant Acinetobacter baumannii

  • Arta Karruli,
  • Antonella Migliaccio,
  • Spyros Pournaras,
  • Emanuele Durante-Mangoni and
  • Raffaele Zarrilli

14 December 2023

Infections caused by carbapenem-resistant Acinetobacter baumannii (CRAB) remain a clinical challenge due to limited treatment options. Recently, cefiderocol, a novel siderophore cephalosporin, and sulbactam-durlobactam, a bactericidal β-lactam&n...

(This article belongs to the Special Issue Molecular Characterization of Gram-Negative Bacteria: Antimicrobial Resistance, Virulence and Epidemiology)
  • Review
  • Open Access
22 Citations
6,706 Views
17 Pages

Cefiderocol in Combating Carbapenem-Resistant Acinetobacter baumannii: Action and Resistance

  • Bahman Yousefi,
  • Setayesh Kashanipoor,
  • Payman Mazaheri,
  • Farnaz Alibabaei and ,
  • Ali Babaeizad,
  • Shima Asli,
  • Sina Mohammadi,
  • Amir Hosein Gorgin,
  • Tahereh Alipour and
  • Majid Eslami
  • + 6 authors+ 1 author

Acinetobacter baumannii (A. baumannii) has emerged as a prominent multidrug-resistant (MDR) pathogen, significantly complicating treatment strategies due to its formidable resistance mechanisms, particularly against carbapenems. Reduced membrane perm...

(This article belongs to the Section Drug Discovery, Development and Delivery)
  • Article
  • Open Access
1 Citations
2,426 Views
10 Pages

11 September 2025

Background: This study aimed to describe cefiderocol prescription and associated patient outcomes at a U.S. academic medical center for various multidrug-resistant organisms (MDRO). Notably, limited real-world data exist on cefiderocol’s clinic...

(This article belongs to the Section Bacterial Diseases)
  • Perspective
  • Open Access
3,605 Views
10 Pages

6 February 2025

Background: Purple urine discoloration, known as purple urine bag syndrome (PUBS), has various etiologies ranging from benign to serious conditions. We present a case of cefiderocol-induced PUBS and review the literature. Methods: A 56-year-old bedri...

  • Review
  • Open Access
276 Citations
15,598 Views
20 Pages

Cefiderocol appears promising, as it can overcome most β-lactam resistance mechanisms (including β-lactamases, porin mutations, and efflux pumps). Resistance is uncommon according to large multinational cohorts, including against isolates r...

(This article belongs to the Special Issue Epidemiology, Prognosis and Antimicrobial Treatment of Extensively Antibiotic-Resistant Bacterial Infections)
  • Case Report
  • Open Access
5 Citations
1,968 Views
7 Pages

Cefiderocol Resistance in Pseudomonas aeruginosa ST175: A Case Report with Genomic Analysis

  • Rosario Fernández Fernández,
  • Alberto Badillo Carrasco,
  • Natalia Chueca Porcuna,
  • Antonio Martínez Cabezas and
  • Manuel Colmenero Ruiz

17 November 2025

Background: Cefiderocol, a novel siderophore cephalosporin, has shown promising activity against multidrug-resistant (MDR) Gram-negative pathogens, including metallo-β-lactamase (MBL) producers. However, emerging reports suggest rapid resistance...

(This article belongs to the Special Issue Fighting the Superbug Surge: Strategies in Antimicrobial Stewardship and Infection Control)
  • Article
  • Open Access
1 Citations
722 Views
10 Pages

Background: To evaluate the potential of cefiderocol as a topical ophthalmic antibiotic by determining the susceptibility of keratitis isolates from an extensive panel of Gram-negative bacterial species to this siderophore-cephalosporin class antibio...

(This article belongs to the Special Issue Antimicrobial Treatment and Antibiotic Use in Ophthalmology)
  • Case Report
  • Open Access
31 Citations
3,617 Views
10 Pages

Intravenous Fosfomycin: A Potential Good Partner for Cefiderocol. Clinical Experience and Considerations

  • Andrea Marino,
  • Stefano Stracquadanio,
  • Edoardo Campanella,
  • Antonio Munafò and ,
  • Maria Gussio,
  • Manuela Ceccarelli,
  • Renato Bernardini,
  • Giuseppe Nunnari and
  • Bruno Cacopardo
  • + 4 authors+ 0 author

Multidrug resistant Gram-negative bacteremia represents a therapeutic challenge clinicians have to deal with. This concern becomes more difficult when causing germs are represented by carbapenem resistant Acinetobacter baumannii or difficult-to-treat...

(This article belongs to the Special Issue Emerging Treatment Options for Multidrug-Resistant Bacterial and Fungal Infections)
  • Brief Report
  • Open Access
31 Citations
5,408 Views
7 Pages

Cefiderocol for Severe Carbapenem-Resistant A. baumannii Pneumonia: Towards the Comprehension of Its Place in Therapy

  • Emanuele Rando,
  • Francesco Vladimiro Segala,
  • Joel Vargas,
  • Cristina Seguiti and ,
  • Gennaro De Pascale,
  • Rita Murri and
  • Massimo Fantoni
  • + 2 authors+ 0 author

Cefiderocol use in A. baumannii pneumonia still represents an important matter of debate. The aim of this study is to describe 13 cases of carbapenem-resistant A. baumannii (CRAB) pneumonia treated with cefiderocol in real-life practice. We retrospec...

(This article belongs to the Special Issue Antibiotics and Infectious Respiratory Diseases)
  • Article
  • Open Access
852 Views
14 Pages

Cefiderocol Susceptibility in Japanese Clinical Enterobacterales Isolates and the Effect of IMP-Type Carbapenemases on Resistance

  • Manke Cai,
  • Go Yamamoto,
  • Shigeto Hamaguchi,
  • Akiko Ueda and ,
  • Ryuji Kawahara,
  • Daisuke Motooka,
  • Yusuke Takahashi and
  • Satoshi Kutsuna
  • + 3 authors+ 0 author

Objectives: Carbapenem-resistant Enterobacterales (CRE) limit treatment options, and cefiderocol’s efficacy can be compromised by regional carbapenemases. In this study, we aimed to characterize cefiderocol susceptibility distribution among Ent...

(This article belongs to the Section Mechanism and Evolution of Antibiotic Resistance)
  • Article
  • Open Access
18 Citations
4,969 Views
10 Pages

Validation and Application of an HPLC-UV Method for Routine Therapeutic Drug Monitoring of Cefiderocol

  • Julia Zimmer,
  • Anka C. Röhr,
  • Stefan Kluge,
  • Jonas Faller and ,
  • Otto R. Frey,
  • Dominic Wichmann and
  • Christina König
  • + 2 authors+ 0 author

28 February 2021

Cefiderocol is a new siderophore cephalosporin approved for the treatment of multidrug resistant bacteria including activity against carbapenem-resistant Enterobacterales and Pseudomonas aeruginosa. As cephalosporins are known for their high pharmaco...

(This article belongs to the Section Pharmacokinetics and Pharmacodynamics of Drugs)
  • Article
  • Open Access
13 Citations
5,638 Views
10 Pages

Pharmacokinetic of Cefiderocol in Critically Ill Patients Receiving Renal Replacement Therapy: A Case Series

  • Simone Mornese Pinna,
  • Silvia Corcione,
  • Amedeo De Nicolò,
  • Giorgia Montrucchio and ,
  • Silvia Scabini,
  • Davide Vita,
  • Ilaria De Benedetto,
  • Tommaso Lupia,
  • Jacopo Mula and
  • Francesco Giuseppe De Rosa
  • + 7 authors+ 2 authors

16 December 2022

Background: Cefiderocol is a novel parenteral siderophore cephalosporin, demonstrating enhanced activity against multidrug-resistant (MDR) Gram-negative bacteria and difficult-to-treat Acinetobacter baumannii (DTR-AB). Plasma-free trough concentratio...

(This article belongs to the Special Issue Clinical Pharmacokinetics and Dose Optimization of Anti-infectives in Critical Care)
  • Article
  • Open Access
7 Citations
1,627 Views
18 Pages

Potential Use of Cefiderocol and Nanosilver in Wound Dressings to Control Multidrug-Resistant Gram-Negative Bacteria

  • Żaneta Binert-Kusztal,
  • Agata Krakowska,
  • Iwona Skiba-Kurek,
  • Magdalena Luty-Błocho and ,
  • Anna Kula,
  • Aldona Olechowska-Jarząb,
  • Przemysław Dorożyński and
  • Tomasz Skalski
  • + 3 authors+ 0 author

23 July 2025

This study evaluated the antimicrobial efficacy of cefiderocol and various forms of silver (ionic and nanoparticulate) as potential components of wound-dressing reagents against both reference and multidrug-resistant (MDR) Gram-negative bacteria. The...

(This article belongs to the Special Issue Applied Chemistry in Europe)
  • Case Report
  • Open Access
2 Citations
2,900 Views
14 Pages

Cefiderocol is a novel cephalosporin antibiotic approved for urinary tract infections and hospital-acquired or ventilator-associated pneumonias caused by difficult-to-treat Gram-negative pathogens. To date, its use in treating difficult-to-treat Gram...

(This article belongs to the Section Antimicrobial Agents and Resistance)
  • Brief Report
  • Open Access
20 Citations
3,850 Views
13 Pages

Assessment of In Vitro Cefiderocol Susceptibility and Comparators against an Epidemiologically Diverse Collection of Acinetobacter baumannii Clinical Isolates

  • Clara Ballesté-Delpierre,
  • Ángel Ramírez,
  • Laura Muñoz,
  • Christopher Longshaw and ,
  • Ignasi Roca and
  • Jordi Vila
  • + 1 author+ 0 author

Cefiderocol is a catechol-substituted siderophore cephalosporin combining rapid penetration into the periplasmic space with increased stability against β-lactamases. This study provides additional data on the in vitro antimicrobial activity of c...

(This article belongs to the Section Mechanism and Evolution of Antibiotic Resistance)
  • Article
  • Open Access
9 Citations
3,841 Views
11 Pages

In Vitro Antimicrobial Activity of the Siderophore Cephalosporin Cefiderocol against Acinetobacter baumannii Strains Recovered from Clinical Samples

  • Davide Carcione,
  • Claudia Siracusa,
  • Adela Sulejmani,
  • Roberta Migliavacca and ,
  • Alessandra Mercato,
  • Aurora Piazza,
  • Luigi Principe,
  • Nicola Clementi,
  • Nicasio Mancini and
  • Jari Intra
  • + 6 authors+ 1 author

27 October 2021

Background: Cefiderocol is a siderophore cephalosporin that exhibits antimicrobial activity against most multi-drug resistant Gram-negative bacteria, including Enterobacterales, Pseudomonas aeruginosa, Acinetobacter baumannii, and Stenotrophomonas ma...

(This article belongs to the Special Issue New Antimicrobial Options in the Clinical Practice of Infections Caused by Difficult-to-Treat Pathogens: A Global Opportunity for Public Health)
  • Article
  • Open Access
2 Citations
1,060 Views
12 Pages

Cefiderocol Targeted Treatment for Multidrug-Resistant Gram-Negative Infections: An Observational Cohort Study

  • Lourdes García-Carnero,
  • Gabriela Abelenda-Alonso,
  • Marc Santos-Puig,
  • Ariadna Padullés and ,
  • Clara Ribera,
  • Alberto Lamiel,
  • Rosa Costa-Primo,
  • Manuel González de Aledo,
  • Rosa Granada and
  • Carlota Gudiol
  • + 12 authors+ 7 authors

Background/Objectives: Infections caused by multidrug-resistant Gram-negative bacteria (MDR-GNB) represent a major therapeutic challenge, particularly in hospitalized and critically ill patients with limited treatment options. Cefiderocol, a novel si...

  • Case Report
  • Open Access
995 Views
10 Pages

Background: Cefiderocol, a siderophore cephalosporin, is approved for the treatment of infections caused by multi-drug-resistant Gram-negative bacteria (MRGN). At present, few data are available on the pharmacokinetics of this substance in critically...

(This article belongs to the Section Antibiotic Therapy in Infectious Diseases)
  • Article
  • Open Access
24 Citations
3,318 Views
10 Pages

Synergistic Effect of Clinically Available Beta-Lactamase Inhibitors Combined with Cefiderocol against Carbapenemase-Producing Gram-Negative Organisms

  • Gabriele Bianco,
  • Paolo Gaibani,
  • Sara Comini,
  • Matteo Boattini and ,
  • Giuliana Banche,
  • Cristina Costa,
  • Rossana Cavallo and
  • Patrice Nordmann
  • + 3 authors+ 0 author

22 November 2022

The role of β-lactamases in reduced susceptibility or resistance to cefiderocol has been supported by recent reports. The purpose of this study was to investigate the in vitro impact of clinically available β-lactamase inhibitors on cefider...

(This article belongs to the Special Issue Multi-Drug Resistant Gram-Negative Infections: Molecular Epidemiology, Microbiological Diagnosis and Antimicrobial Treatment)
  • Article
  • Open Access
1,602 Views
12 Pages

27 February 2026

Background/Objectives: Acinetobacter baumannii is a leading cause of healthcare-associated infections and is frequently associated with multidrug resistance, severely limiting therapeutic options. The increasing prevalence of carbapenem-resistant A. ...

(This article belongs to the Special Issue Advancing and Standardising Antimicrobial Susceptibility and Resistance Detection Methodology)
  • Article
  • Open Access
4 Citations
1,817 Views
14 Pages

In Vitro Activity of Cefiderocol Against Multi-Drug-Resistant Gram-Negative Clinical Isolates in Romania

  • Anda Baicus,
  • Valentina Daniela Sisu,
  • Andreia Domnica Tatar,
  • Adrian Gherghel and ,
  • Diana Gabriela Iacob,
  • Corina Silvia Pop and
  • Catalin Florin Cirstoiu
  • + 2 authors+ 0 author

5 November 2025

Background/Objectives: Gram-negative bacteria with acquired carbapenem resistance have become increasingly common in serious infections. This study aimed to evaluate the in vitro activity of cefiderocol against multidrug-resistant Gram-negative clini...

  • Article
  • Open Access
2 Citations
2,650 Views
13 Pages

4 November 2024

Background/Objectives: The necessity for ground-breaking treatments for Gram-negative infections is evident. The World Health Organization, the Infectious Diseases Society of America, and the European Commission have highlighted the critical insuffic...

  • Article
  • Open Access
16 Citations
4,626 Views
9 Pages

Role of Cefiderocol in Multidrug-Resistant Gram-Negative Central Nervous System Infections: Real Life Experience and State-of-the-Art

  • Alessio Sollima,
  • Francesco Rossini,
  • Paola Lanza,
  • Carlo Pallotto and ,
  • Marianna Meschiari,
  • Ivan Gentile,
  • Roberto Stellini,
  • Angelica Lenzi,
  • Alice Mulé and
  • Alberto Matteelli
  • + 13 authors+ 8 authors

Cefiderocol is a new molecule effective against multidrug-resistant (MDR) Gram-negative pathogens. Currently, there is limited evidence regarding the use of cefiderocol in central nervous system (CNS) infections. Data on the cerebrospinal fluid penet...

(This article belongs to the Special Issue Antimicrobial Treatment and Management of Central Nervous System Infections)
  • Article
  • Open Access
20 Citations
4,872 Views
12 Pages

Human Serum Proteins and Susceptibility of Acinetobacter baumannii to Cefiderocol: Role of Iron Transport

  • Casin Le,
  • Camila Pimentel,
  • Fernando Pasteran,
  • Marisel R. Tuttobene and ,
  • Tomás Subils,
  • Jenny Escalante,
  • Brent Nishimura,
  • Susana Arriaga,
  • Aimee Carranza and
  • Maria Soledad Ramírez
  • + 11 authors+ 6 authors

Cefiderocol, a recently introduced antibiotic, has a chemical structure that includes a cephalosporin that targets cell wall synthesis and a chlorocatechol siderophore moiety that facilitates cell penetration by active iron transporters. Analysis of...

(This article belongs to the Section Drug Discovery, Development and Delivery)
  • Case Report
  • Open Access
1,528 Views
10 Pages

Cefiderocol as a Successful Therapy for Osteomyelitis Due to XDR Pseudomonas aeruginosa: A Case Report and Literature Review

  • Alice Mulè,
  • Anna Cambianica,
  • Alberto Matteelli,
  • Silvia Lorenzotti and ,
  • Angelica Lenzi,
  • Francesco Rossini,
  • Alessio Sollima,
  • Susanna Capone and
  • Francesco Castelli
  • + 4 authors+ 0 author

28 November 2025

Background: Carbapenem-resistant Enterobacterales and difficult-to-treat resistance (DTR) Pseudomonas aeruginosa are a growing public health issue. Cefiderocol demonstrated activity against β-lactamase-producing Gram-negative bacteria (GNB). How...

(This article belongs to the Section Antibiotic Therapy in Infectious Diseases)
  • Case Report
  • Open Access
13 Citations
5,061 Views
8 Pages

The Use of Cefiderocol as Salvage Therapy in an Infant Receiving ECMO and Continuous Renal Replacement Therapy

  • Stefania Mercadante,
  • Costanza Tripiciano,
  • Lorenza Romani,
  • Matteo Di Nardo and ,
  • Gabriella Bottari,
  • Bianca Maria Goffredo,
  • Raffaele Simeoli,
  • Isabella Guzzo,
  • Laura Lancella and
  • Maia De Luca
  • + 6 authors+ 1 author

Background: Infections caused by antimicrobial-resistant (AMR) pathogens are increasing worldwide, representing a serious global public health issue with high morbidity and mortality rates The treatment of Pseudomonas aeruginosa (PA) infections has b...

(This article belongs to the Special Issue Antimicrobials Agents: Latest Advances and Prospects)
  • Review
  • Open Access
40 Citations
16,202 Views
16 Pages

An Overview of Cefiderocol’s Therapeutic Potential and Underlying Resistance Mechanisms

  • Sara Domingues,
  • Tiago Lima,
  • Maria José Saavedra and
  • Gabriela Jorge Da Silva

21 June 2023

Antimicrobial resistance continues to increase globally and treatment of difficult-to-treat (DTT) infections, mostly associated with carbapenem-resistant (CR) Pseudomonas aeruginosa, CR Acinetobacter baumannii, and CR- and third-generation-cephalospo...

(This article belongs to the Special Issue Bacteriocin, Antimicrobial Peptide, and Antibiotics: Current Insights and Application)
  • Article
  • Open Access
7 Citations
2,582 Views
9 Pages

17 October 2024

Background: An overlooked factor in the efficacy of topical antibiotics to treat bacterial keratitis is the state of the corneal epithelium. Recently, we evaluated topical cefiderocol for the treatment of extensively drug-resistant (XDR) Pseudomonas ...

(This article belongs to the Collection Antibiotics in Ophthalmology Practice)
  • Article
  • Open Access
4 Citations
1,678 Views
13 Pages

Impact of Susceptibility Testing Methodology on the Positioning of Cefiderocol and Aztreonam-Avibactam Against Metallo-β-Lactamase-Producing Gram-Negative Bacteria

  • Fernando del Nogal-Labrador,
  • Beatriz González-Blanco,
  • María Isabel Sanz,
  • Raúl Recio and ,
  • Patricia Brañas,
  • Irene Muñoz-Gallego,
  • Esther Viedma and
  • Jennifer Villa
  • + 3 authors+ 0 author

Background/Objectives: The impact of antimicrobial susceptibility testing methodology on the categorization and positioning of cefiderocol and aztreonam-avibactam against metallo-β-lactamase (MBL)-producing Gram-negative bacilli remains unclear....

(This article belongs to the Section Antibiotics Use and Antimicrobial Stewardship)
  • Communication
  • Open Access
10 Citations
8,811 Views
6 Pages

Cefiderocol Protects against Cytokine- and Endotoxin-Induced Disruption of Vascular Endothelial Cell Integrity in an In Vitro Experimental Model

  • Dagmar Hildebrand,
  • Jana Böhringer,
  • Eva Körner,
  • Ute Chiriac and ,
  • Sandra Förmer,
  • Aline Sähr,
  • Torsten Hoppe-Tichy,
  • Klaus Heeg and
  • Dennis Nurjadi
  • + 4 authors+ 0 author

The severe course of bloodstream infections with Gram-negative bacilli can lead to organ dysfunctions and compromise the integrity of the vascular barrier, which are the hallmarks of sepsis. This study aimed to investigate the potential effect of cef...

(This article belongs to the Topic Novel Antimicrobial Agents: Discovery, Design and New Therapeutic Strategies)
  • Brief Report
  • Open Access
2 Citations
3,194 Views
10 Pages

Comparison of Different Methods for Assaying the In Vitro Activity of Cefiderocol against Carbapenem-Resistant Pseudomonas aeruginosa Strains: Influence of Bacterial Inoculum

  • Celia García-Rivera,
  • Antonia Sánchez-Bautista,
  • Mónica Parra-Grande,
  • Andrea Ricart-Silvestre and ,
  • María Paz Ventero,
  • Iryna Tyshkovska,
  • Esperanza Merino and
  • Juan Carlos Rodríguez Díaz
  • + 3 authors+ 0 author

Carbapenem-resistant Pseudomonas aeruginosa infections represent a critical public health concern, highlighting the need for the development of effective antibiotics. Cefiderocol demonstrated potent in vitro activity against Pseudomonas aeruginosa, p...

(This article belongs to the Special Issue Antibiotics Resistance and Molecular Epidemiology of Carbapenem-Resistance Bacteria)
  • Article
  • Open Access
9 Citations
3,050 Views
11 Pages

29 September 2021

In the last two decades, the worldwide dissemination of multidrug-resistant Gram-negative bacteria (MDR-GNB) has continued. Therapy options for such infections caused by MDR-GNB remain scarce, and only few new antimicrobial agents have been granted m...

(This article belongs to the Special Issue Resistant Mechanisms and Novel Antibiotics of Carbapenem-Resistant Crisis)
  • Article
  • Open Access
2 Citations
1,356 Views
9 Pages

22 October 2025

Background/Objectives: Bloodstream infections (BSIs) caused by carbapenem-resistant Enterobacterales (CREs) are a growing public health threat due to limited therapeutic options and high mortality. In Turkey, oxacillinase-48 (OXA-48) producers predom...

  • Article
  • Open Access
23 Citations
4,201 Views
16 Pages

Induced Heteroresistance in Carbapenem-Resistant Acinetobacter baumannii (CRAB) via Exposure to Human Pleural Fluid (HPF) and Its Impact on Cefiderocol Susceptibility

  • Vyanka Mezcord,
  • Jenny Escalante,
  • Brent Nishimura,
  • German M. Traglia and ,
  • Rajnikant Sharma,
  • Quentin Vallé,
  • Marisel R. Tuttobene,
  • Tomás Subils,
  • Ingrid Marin and
  • María S. Ramirez
  • + 10 authors+ 5 authors

Infections caused by Carbapenem-resistant Acinetobacter baumannii (CRAB) isolates, such as hospital-acquired pneumonia (HAP), bacteremia, and skin and soft tissue infections, among others, are particularly challenging to treat. Cefiderocol, a chloroc...

(This article belongs to the Special Issue Antimicrobial Resistance, Molecular Epidemiology and Emerging Therapeutic Strategies in Carbapenem-Resistant Gram-Negative Bacteria)
  • Article
  • Open Access
489 Views
14 Pages

In Vitro Activity of Eravacycline, Aztreonam–Avibactam, and Cefiderocol Against Multidrug-Resistant Gram-Negative Clinical Isolates from a Romanian Tertiary Hospital

  • Anda Baicus,
  • Valentina Daniela Sisu,
  • Andreia Domnica Tatar,
  • Lore-Dana Barcer and ,
  • Elena Andreea Birlescu,
  • Monica Dugaesescu and
  • Catalin Florin Cirstoiu
  • + 2 authors+ 0 author

22 September 2026

Background/Objectives: Carbapenem-resistant Gram-negative bacteria—especially NDM- and OXA-48-producing Klebsiella pneumoniae and carbapenem-resistant Acinetobacter baumannii (CRAB)—have limited treatment options, and in vitro data from E...

(This article belongs to the Special Issue Antimicrobial Resistance in Clinical Isolates: Surveillance, Preparedness and Public Health Challenges)
  • Article
  • Open Access
2 Citations
775 Views
13 Pages

Unraveling Cefiderocol Resistance in NDM- and OXA-48-like Co-Producing Klebsiella pneumoniae Isolates Through Integrated Genomic and Phenotypic Analysis

  • Simone Ambretti,
  • Raul Cetatean,
  • Benedetta Secci,
  • Jessica Landi and ,
  • Alessia Cantiani and
  • Claudio Foschi
  • + 1 author+ 0 author

Background/Objectives: The co-production of New Delhi metallo-β-lactamases (NDM) and OXA-48-like carbapenemases in Klebsiella pneumoniae represents a major therapeutic challenge due to extensive drug resistance and limited treatment options. Thi...

(This article belongs to the Special Issue Epidemiology and Genomics of Antimicrobial Resistance of Difficult-to-Treat Pathogens)
  • Article
  • Open Access
21 Citations
3,909 Views
12 Pages

Cefiderocol Efficacy in a Real-Life Setting: Single-Centre Retrospective Study

  • Gabriele Palermo,
  • Alice Annalisa Medaglia,
  • Luca Pipitò,
  • Raffaella Rubino and ,
  • Manuela Costantini,
  • Salvatore Accomando,
  • Giovanni Maurizio Giammanco and
  • Antonio Cascio
  • + 3 authors+ 0 author

The current carbapenem-resistant gram-negative bacteria (CR-GN) treatment guidelines lack strong evidence about cefiderocol (CFD) efficacy against CR-GN, especially CRAB. The study’s purpose is to evaluate the effectiveness of CFD in a real-lif...

(This article belongs to the Section Antibiotic Therapy in Infectious Diseases)
  • Article
  • Open Access
5 Citations
2,214 Views
16 Pages

High Prevalence of Cefiderocol Resistance Among New Delhi Metallo-β-Lactamase Producing Klebsiella pneumoniae High-Risk Clones in Hungary

  • Lilla Buzgó,
  • Zsanett Kiss,
  • Dániel Göbhardter,
  • Virág Lesinszki and ,
  • Erika Ungvári,
  • Zoltán Rádai,
  • Levente Laczkó,
  • Ivelina Damjanova,
  • Gábor Kardos and
  • Ákos Tóth
  • + 5 authors+ 0 author

Background/Objectives: The global spread of carbapenemase-producing K. pneumoniae (CPKP) strains represent a severe public health threat due to very limited choice of antibacterial therapy. Cefiderocol, a novel siderophore-cephalosporin, may represen...

(This article belongs to the Section Antibiotic Therapy in Infectious Diseases)
  • Article
  • Open Access
89 Citations
10,878 Views
19 Pages

Cefiderocol-Based Combination Therapy for “Difficult-to-Treat” Gram-Negative Severe Infections: Real-Life Case Series and Future Perspectives

  • Davide Fiore Bavaro,
  • Alessandra Belati,
  • Lucia Diella,
  • Monica Stufano and ,
  • Federica Romanelli,
  • Luca Scalone,
  • Stefania Stolfa,
  • Luigi Ronga,
  • Leonarda Maurmo and
  • Annalisa Saracino
  • + 9 authors+ 4 authors

Cefiderocol is a new cephalosporin displaying against extensively resistant (XDR) Gram-negative bacteria. We report our experience with cefiderocol-based combination therapies as “rescue” treatments in immunocompromised or critically ill patients or...

(This article belongs to the Special Issue Current and Novel Antimicrobial Strategies for Bacterial and Fungal Infections by Resistant Organisms)
  • Article
  • Open Access
281 Views
32 Pages

Paired In Vitro Susceptibility of Cefiderocol and Colistin in Colistin-Resistant, Extensively Drug-Resistant Gram-Negative Bacilli: A Single-Centre, MIC-Based Analysis of 236 Clinical Isolates

  • Elena Hogea,
  • Nicolae Ciprian Pilut,
  • Felix Bratosin,
  • Andra-Nicole Rusnac and ,
  • Oana Plavitu,
  • Livia Stanga and
  • Horia Silviu Branea
  • + 2 authors+ 0 author

Extensively drug-resistant (XDR) Gram-negative bacilli increasingly exhaust therapeutic options, leaving colistin and cefiderocol as last-resort agents. We assessed whether cefiderocol retains in vitro activity against colistin-resistant isolates, wi...

(This article belongs to the Special Issue Cefiderocol: An Overview of Antibacterial Activity and Resistance Mechanisms)

of 5